Literature DB >> 21503830

Overlap syndrome of autoimmune hepatitis and primary biliary cirrhosis triggered by fluvastatin.

Satoshi Nakayama1, Naoya Murashima.   

Abstract

Although statins are generally well-tolerated drugs, recent cases of autoimmune hepatitis (AIH) associated with their use have been reported. A 59-year-old Japanese man reported with liver damage, which appeared one month after beginning treatment with fluvastatin and continued after discontinuation of the drug. Although drug-induced liver injury was possible, positive autoantibody tests (antinuclear antibodies >1/1280, anti-mitochondrial M2 antibodies 21 index value) also suggested autoimmune liver disease. Liver biopsy findings were consistent with an overlap of autoimmune hepatitis and primary biliary cirrhosis. Treatment with prednisone and ursodeoxycholic acid led to a good response. In this patient, manifestation of AIH and primary biliary cirrhosis overlap syndrome was possibly triggered by statin use. Autoimmune liver disease should be considered as a possible diagnosis in patients with evidence of prolonged liver damage after discontinuation of statins.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21503830     DOI: 10.1007/s12664-011-0092-x

Source DB:  PubMed          Journal:  Indian J Gastroenterol        ISSN: 0254-8860


  10 in total

1.  Drug-induced autoimmune hepatitis: clinical characteristics and prognosis.

Authors:  Einar Björnsson; Jayant Talwalkar; Sombat Treeprasertsuk; Patrick S Kamath; Naoki Takahashi; Schuyler Sanderson; Matthias Neuhauser; Keith Lindor
Journal:  Hepatology       Date:  2010-06       Impact factor: 17.425

2.  Autoimmune hepatitis triggered by statins.

Authors:  Vamsee Alla; Joseph Abraham; Junaid Siddiqui; Dimple Raina; George Y Wu; Naga P Chalasani; Herbert L Bonkovsky
Journal:  J Clin Gastroenterol       Date:  2006-09       Impact factor: 3.062

Review 3.  Statins and hepatotoxicity: focus on patients with fatty liver.

Authors:  Naga Chalasani
Journal:  Hepatology       Date:  2005-04       Impact factor: 17.425

4.  Rosuvastatin-associated hepatitis with autoimmune features.

Authors:  L M M Wolters; H R Van Buuren
Journal:  Eur J Gastroenterol Hepatol       Date:  2005-05       Impact factor: 2.566

5.  Autoimmune hepatitis after treatment with fluvastatin.

Authors:  Agustin Castiella; Javier Fernandez; Eva Zapata
Journal:  Liver Int       Date:  2007-05       Impact factor: 5.828

Review 6.  Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review.

Authors:  B Noël
Journal:  J Eur Acad Dermatol Venereol       Date:  2007-01       Impact factor: 6.166

7.  Fluvastatin and hepatic reactions: a signal from spontaneous reporting in Italy.

Authors:  Anita Conforti; Lara Magro; Ugo Moretti; Stefania Scotto; Domenico Motola; Francesco Salvo; Barbara Ros; Roberto Leone
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

8.  Autoimmune hepatitis revealed by atorvastatin.

Authors:  Nicoletta Pelli; Maurizio Setti; Paola Ceppa; Carlo Toncini; Francesco Indiveri
Journal:  Eur J Gastroenterol Hepatol       Date:  2003-08       Impact factor: 2.566

9.  Simplified criteria for the diagnosis of autoimmune hepatitis.

Authors:  Elke M Hennes; Mikio Zeniya; Albert J Czaja; Albert Parés; George N Dalekos; Edward L Krawitt; Paulo L Bittencourt; Gilda Porta; Kirsten M Boberg; Harald Hofer; Francesco B Bianchi; Minoru Shibata; Christoph Schramm; Barbara Eisenmann de Torres; Peter R Galle; Ian McFarlane; Hans-Peter Dienes; Ansgar W Lohse
Journal:  Hepatology       Date:  2008-07       Impact factor: 17.425

Review 10.  Drug-induced liver injury associated with statins.

Authors:  Mark W Russo; Martin Scobey; Herbert L Bonkovsky
Journal:  Semin Liver Dis       Date:  2009-10-13       Impact factor: 6.115

  10 in total
  1 in total

1.  Detection of Anti-mitochondrial Antibodies Accompanied by Drug-induced Hepatic Injury due to Atorvastatin.

Authors:  Noriyuki Kuniyoshi; Hiroshi Miyakawa; Kotaro Matsumoto; Hiromichi Tsunashima; Katsunori Sekine; Takayuki Tsujikawa; Masatoshi Mabuchi; Shinpei Doi; Kentaro Kikuchi
Journal:  Intern Med       Date:  2019-06-07       Impact factor: 1.271

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.